OTCMECRTF
Market cap344mUSD
Dec 31, Last price
1.25USD
1Q
20.19%
Jan 2017
19,741.27%
Name
Atex Resources Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
116.87%
Rev. gr., 5y
%
Revenues
0k
Net income
-29m
L+1,161.55%
CFO
-23m
L+4,917.68%
Earnings
May 28, 2025
Profile
Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for oncology and chronic fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other cancers and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for cancer and fibrotic disease indication. It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑09 | 2022‑09 | 2021‑09 | 2020‑09 | 2019‑09 | 2018‑09 | 2017‑09 | 2016‑09 | 2015‑09 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 29,809 | 2,623 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (29,809) | (2,623) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (1,091) | (329) | |||||||
Tax Rate | |||||||||
NOPAT | (28,718) | (2,294) | |||||||
Net income | (28,942) 1,161.55% | (2,294) 142.99% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 9,782 | 20,930 | |||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 46 | ||||||||
Long-term debt | 9,670 | ||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | (4,991) | (15,643) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (22,920) | (457) | |||||||
CAPEX | (719) | (588) | |||||||
Cash from investing activities | (2,271) | (8,425) | |||||||
Cash from financing activities | 22,737 | 24,338 | |||||||
FCF | (19,302) | (9,736) | |||||||
| Balance | |||||||||
Cash | 13,168 | 15,623 | |||||||
Long term investments | 1,539 | 20 | |||||||
Excess cash | 14,707 | 15,643 | |||||||
Stockholders' equity | 2,468 | 26,287 | |||||||
Invested Capital | 13,545 | 11,982 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 153,650 | 95,464 | |||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | (29,669) | (2,619) | |||||||
EV/EBITDA | |||||||||
Interest | 671 | 8 | |||||||
Interest/NOPBT | |||||||||